Purpose of Review We review studies published since 2014 that examined team-based care strategies and involved pharmacists to improve blood pressure (BP). We then discuss opportunities and challenges to sustainment of team-based care models in primary care clinics. Recent Findings Multiple studies presented in this review have demonstrated that team-based care including pharmacists can improve BP management. Studies highlighted the cost-effectiveness of a team-based pharmacy intervention for BP control in primary care clinics. Little information was found on factors influencing sustainability of team-based care interventions to improve BP control. Summary Future work is needed to determine the best populations to target with team-based BP programs and how to implement team-based approaches utilizing pharmacists in diverse clinical settings. Future studies need to not only identify unmet clinical needs but also address reimbursement issues and stakeholder engagement that may impact sustainment of team-based care interventions.
Introduction
Hypertension is a leading risk factor for stroke and cardiovascular disease [1] [2] [3] . Nearly 75 million US adults have hypertension [1, 3] . Fortunately, effective treatment for hypertension is available: several clinical trials have demonstrated that antihypertensive medications reduce cardiovascular events [4] . For example, even a 5-mmHg difference in systolic blood pressure (BP) over 3-5 years can reduce the risk of cardiovascular complications and strokes by 25-30% [5] . However, even with the existence of effective treatment, among adults with hypertension, 50% remain uncontrolled [2, 3] .
One effective approach to improving BP control is teambased primary care. Studies have consistently shown that team-based care can improve BP control, particularly when pharmacists or nurses are involved in the patient's primary care management [6] [7] [8] [9] [10] [11] . Team-based care has been defined by the National Academy of Medicine (formerly known as the Institute of Medicine) as "...the provision of health services to individuals, families, and/or their communities by at least two health providers who work collaboratively with patients and their caregivers -to the extent preferred by each patient -to accomplish shared goals within and across settings to achieve coordinated, high-quality care" [12, 13] . A team-based care approach promotes comprehensive, coordinated, efficient, and effective healthcare [13] [14] [15] [16] . Thus, it is a critical component of the Patient-Centered Medical Home (PCMH) model [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] . Since 2014, the National Committee for Quality Assurance (NCQA) has included team-based care as a standard that health systems must meet in order to achieve the highest level of PCMH recognition. A team-based care approach to primary care is not a new concept, but the implementation and sustainment of team-based care models in primary care settings has remained a substantial challenge [29] .
In this paper, we review recent studies that examined teambased care strategies that involve pharmacists to improve BP. We also discuss opportunities and challenges to sustainment of team-based care models in primary care settings while offering strategies to increase likelihood of sustainment of these interventions.
Review of Studies Published Since 2014
Numerous studies published over the last four decades have shown that involving nurses or pharmacists on the primary care team can significantly improve patient BP control [29] . Many of these studies, however, were small, single-site studies and did not control for important confounders that are known to influence BP. We will discuss larger, recently published studies that have reported clinical and economic outcomes.
Carter et al. (2015) conducted a prospective, cluster-randomized, three-arm trial in 32 primary care clinics from 15 states to evaluate if clinics randomized to receive the physician-pharmacist collaborative model intervention would achieve better BP at 9 months compared to usual care [30•] . Pharmacists were embedded within their respective primary care office and focused on management of hypertension. Twelve clinics were assigned to usual care, eleven clinics to receive a 9-month (brief) intervention, and nine clinics to receive a 24-month (extended) intervention. Racial minorities composed 54% of the overall study population. For the purposes of the primary outcome, the brief and extended intervention arms were combined. Selected secondary outcomes reported here were to assess mean BP differences at 9 months and whether patients from racial minority groups who received the intervention had lower systolic BP control at 24 months compared to usual care. The intervention groups were no longer combined for the 24-month time point. Primary outcome results showed BP control was 43% in the combined intervention group (n = 345) and 34% in the usual care group (n = 194) at 9 months (adjusted OR 1.57 [95% CI 0.99-2.50], p = 0.059). There was a significant reduction in systolic BP in the intervention group compared to the usual care group (− 6.1 mmHg, p = 0.002) for all subjects and also in those from racial minorities (− 6.1 mmHg, p = 0.009). The effect of the intervention was sustained in racial minority groups for both the brief intervention − 4.31 mmHg (p = 0.048) versus usual care and the extended intervention − 4.93 mmHg (p = 0.011) versus usual care. A subsequent evaluation found that the intervention reduced the gap in BP reductions for racial minorities, those with lower income or less education and those without insurance [31] . While the pharmacists addressed medication adherence, most interventions included medication intensification with additions of drugs or increased doses [32] . Formative evaluations were also conducted with all the on-site pharmacists to evaluate barriers to fully implementing and sustaining the clinical intervention. The vast majority of pharmacists indicated the intervention was very difficult to add to their existing responsibilities (e.g., physician education, patient care). Most pharmacists felt that they did not have enough time to fully implement the intervention and that more pharmacist time would be required for full implementation and sustainment. The second frequently cited problem was the large number of patients from low socioeconomic groups who failed to make followup appointments, often due to travel or work responsibilities [33, 34] . Tsuyuki et al. (2015) report results from a multisite, randomized, controlled trial comparing enhanced pharmacist care versus usual care in 23 Canadian sites [35•] . Sites included community pharmacies, primary care clinics, or hospital outpatient clinics. Enhanced pharmacy care included pharmacist assessment of and counseling about cardiovascular disease (CVD) risk and BP control, review of current antihypertensive medications, and prescribing/titrating drug therapy as needed, in addition to what the usual care group received: a wallet card for recording BP measurements, lifestyle advice, and written information on hypertension. Medication therapy changes and assessment information was relayed to the patient's primary care provider. After the 6-month intervention period, intervention patients (n = 181) had a reduction in systolic BP of − 6.6 mmHg (p = 0.006) and diastolic BP of − 3.2 mmHg (p = 0.01) versus usual care patients (n = 67). This study is significant in that pharmacists had independent prescriptive authority after the pharmacist met a series of requirements, expanding the pharmacists' scope of care. Tsuyuki et al. (2016) also found improvement in systolic and diastolic BPs in their randomized trial of 56 Canadian community pharmacies that evaluated community pharmacist case finding on CVD risk [36] . Panattoni et al. (2017) report results from their team-based care model that included a redesigned primary care visit to facilitate patient self-management of hypertension and diabetes [37] . This was a quasi-experimental study comparing their team-based care model (n = 38 physicians) to usual care (n = 37 physicians) within the Palo Alto Medical Foundation. The redesigned workflow expanded the medical assistant's previsit role to collect more patient information including taking patient measurements, while the physician offered evidencebased patient self-management support. An unlicensed health coach worked with selected patients between physician visits. Additional support was given to patients post-visit and included a health coaching program and/or a pharmacist who provided medication reconciliation. Patients in the intervention group (n = 3156) aged 18-75 years living with diabetes experienced a decrease of − 1.13 mmHg (95% CI − 2.23 to − 0.04) for diastolic BP and − 0.47 (95% CI − 0.61 to − 0.33) decline in A1c over the 6-month intervention period when compared to usual care (n = 8034). However, the authors did not find these results clinically meaningful, and these findings were not sustained through 12 months after the index visit. An evaluation of the intervention was conducted, and researchers found that certain fidelity measures, or the degree to which the intervention was consistently carried out, varied across measures. Researchers proposed that the complexity of the intervention and lack of physician engagement were possible reasons, among others, that contributed to low fidelity. Suggested future research included a qualitative assessment of the barriers that may impeded intervention uptake.
Cost-effectiveness of Team-Based Care
Cost-effectiveness evaluations of team-based care are of three types: incremental cost-effectiveness studies of randomized controlled trials, Markov studies where the results of trials are used to build simulations of long-term costs, and observational studies of existing team-based care within clinics.
Incremental Cost-effectiveness Studies
Incremental cost-effectiveness studies add the costs of the intervention from a randomized, controlled trial and the resulting healthcare costs during the study period and compare these costs to the study outcomes. However, no long-term costs or outcomes are considered. Randomized controlled trials are the gold standard for determining the effects of an intervention, but the results are often not generalizable outside of the controlled study environment.
Polgreen et al. [38] conducted an incremental costeffectiveness analysis of the data from Carter et al. (mentioned earlier [30•] ). The analysis was performed from a societal point of view. Costs were assigned to medications (average wholesale price), pharmacist time, and physician time. Patient-specific drug costs for the 9-month period were $1223.91 in the intervention group and $1146.27 in the control group. Pharmacists had 2036 encounters for 360 patients with an average of 155 min total. There were 439 patients who had one or more physician visit. The control group averaged three physician visits, and the intervention averaged two physician visits during the study. Mean total costs were $1462.87 in the intervention group and $1259.94 in the control group for a difference of $202.93. Because average systolic BP decreased by 6.1 mmHg, in the intervention group compared to that in the control group, the cost-effectiveness was $33.27/ mmHg systolic BP. In addition, 43% of patients had controlled BP in the intervention group versus 34% of patients in the control group; thus, the cost to lower BP control in the population by one percentage point was $22.55.
Simpson et al. [39•] analyzed a trial of pharmacist/ physician collaboration in five clinics in Edmonton, Alberta, Canada [40] from the payer's perspective with data from 123 patients with type 2 diabetes. They compared a control group with usual care to an intervention group where patients met with pharmacists who performed a medication history and measured BP. The pharmacist made recommendations to the physician based on the patient's medical history and current medications. Pharmacists contacted the patients to determine if any medication issues arose and to address them. All patients were interviewed after 1 year to record changes in BP and cardiovascular risk factors. Costs in Canadian dollars (CAD) were estimated for the intervention itself, medications, physician services, emergency department visits, and inpatient stays. Pharmacists spent 1 h per patient at baseline and an average of 2 h in follow-up visits, including an average of six phone calls and two in-person visits. Intervention patients had fewer specialist visits (− $42 CAD) and inpatient stays (− $407 CAD), but more emergency department visits (+ $41 CAD) compared to controls. The cost of the intervention was $226 CAD per patient, and the total costs during the study were $1803 CAD per patient for the intervention group and $1993 CAD for the control group. The total costs for the intervention cost less (− $190 CAD) than the control group, and the intervention was effective with 0.26% reduction in annual cardiovascular risk. For a variety of simulated costs and health effects, 95% of the replications were costeffective at $4000 CAD per 1% reduction in cardiovascular risk. With a threshold of $33,215 CAD, 99% of replications were cost-effective. [42] were used to estimate disease-specific mortality and other events that are associated with disease progression. Then, commonly used utility values [43] were applied to quantify health-related quality of life for the different health states. These studies took a wide range of possible scenarios into account. However, all forecasting has flaws in that future treatments as well as diseases may change patients' trajectories.
Markov Models of Cost-effectiveness
Specifically, Marra et al. [42] risk. The intervention affected the risk scores via reductions in BP. In this study, the intervention is ongoing, and thus there is no deterioration in BP control over time. The cost of the intervention included pharmacist-patient visits which occur six times in the first year and four times per year in the following years. The cost of the first visit each year was $125 CAD, and other visits were $25 CAD. They also assumed that patients who received the intervention would have $30 CAD more drug costs per year than control patients. They found that a difference of 18.3 mmHg between the control and intervention groups led to a reduction in risk equivalent to two fewer cardiovascular events for every ten intervention patients, and additional 0.3 years of life and an additional 0.4 years of qualityadjusted life years. In terms of costs, the intervention costs $7145 CAD for pharmacist visits and $1584 for additional medications, but costs fell by $14,002 CAD for CVD and $1092 CAD for chronic kidney disease, resulting in cost savings of $6365 CAD over 30 years per patient. Sensitivity analyses where the effectiveness of the intervention, the length of effectiveness of the intervention, and shorter time horizons also gave favorable results. In all cases, the intervention was costeffective given a $40,000/quality-adjusted-life-year threshold.
Kulchaitanaroaj et al. [41• ] also performed a Markov model of the long-term cost-effectiveness of a pharmacistphysician collaboration from the payer's perspective. This study was based on data from earlier studies of pharmacistphysician collaborations conducted by Carter et al. [6, 7] . In an earlier incremental cost-effectiveness study similar to Polgreen et al. (2015) and Simpson et al. (2015) , the researchers determined the costs during the study for pharmacist and physician time, and overhead costs, laboratory tests, and drugs were $445.75 for the control group and $774.90 for the intervention group [44] . Unlike Marra et al., Kulchaitanaroaj et al. assumed that the BP benefit of the study would deteriorate over time such that the BP in the control and intervention groups would be equal after year 5. Costs were higher for the intervention group by $3817.54 per person over their lifetime, but quality-adjusted life years increased by 0.14. Given a $50,000/quality-adjusted-life-year threshold, 48.6% of the interventions simulated were cost-effective. The authors found that these interventions were most effective for the highest risk patients.
Observational Studies
The third type of cost-effectiveness study is observational. In this type of study, previously collected clinical data from an ongoing intervention is abstracted from electronic medical records (EMRs) or insurance claims. This type of study is helpful in that the effects of the intervention are witnessed "in real life." However, the effectiveness of the intervention is calculated for those who were selected for the intervention, and patients are usually not chosen for the intervention randomly.
Kislan et al. [45• ] performed a retrospective matched cohort study using Medicare claims for patients from University of North Carolina Health Care. The intervention group consisted of patients referred to a Clinical Pharmacist Practitioner (CCP) and seen at least twice from 2008 to 2011. The control group saw only the primary care provider (PCP) at least twice. Patients with hypertension, diabetes mellitus, or peripheral neuropathy were included. The outcome for patients with hypertension was BP control. Costs were collected for outpatient medications, pharmacist and physician visits, and emergency department visits and hospitalizations. There were 12,065 patients in the control group and 378 patients in the intervention group, matched by gender, age, and disease. Visits with CPPs cost 20.7% less than visits with PCPs. Emergency department visits and inpatient visits were lower in the CCP group, but hypertension medication changes were higher in the CCP group. Total costs for the CCP group were 1.46% lower when compared to those for the PCP group.
Opportunities and Challenges to Sustaining Team-Based Care Innovations in Primary Care Settings
The following discussion is not exhaustive but intended to underscore the complexities involved when sustaining teambased care models in primary care settings. Adoption and subsequent sustainment of team-based primary care interventions remain slow in our current healthcare environment [29] . We offer perspectives documented in the literature for strategies to examine potential sustainability of team-based care interventions as well as factors that may influence sustainability. We supplement the discussion with personal perspectives our team experienced during our federally funded team-based clinical trials [6, 8, 11, 38, [46] [47] [48] [49] .
Drawing upon the emerging field, implementation science, we believe an attention to sustainability of team-based care models and the importance for primary care clinics to adapt to their ever-changing environment are greatly needed [8] . Sustainability has been broadly defined as the "long-term integration of effective interventions within specific settings" [50] . Sustainability is an integral implementation outcome [51] , yet sustainability of team-based models across primary care settings remains a challenge. Implementing a team-based care model in a primary care clinic does not guarantee the model will be sustained [51] . As such, more needs to be known about how individual and organizational-level factors interact and influence team-based care model sustainment [52] [53] [54] [55] [56] .
Sustainment of the planned team-based care intervention should be considered early during intervention design.
Designing for dissemination and implementation (D4D&I) is the set of activities performed throughout intervention planning, development, and evaluation to increase the likelihood the intervention will be disseminated, implemented, and ultimately sustained in desired settings [57, 58] . Under federal grant funding, our team has designed and refined a teambased care intervention that utilizes remote clinical pharmacists to support under-resourced primary care providers with CVD management and achievement of key performance measures (e.g., BP control) [47, 48, 59] . We are in the process of transitioning from research grant funding to a self-sustained model. As part of this transition, we conducted interviews with clinic stakeholders and identified specific factors we need to address before sustainment can be realized: reimbursement for services, stakeholder engagement, EMR access, and identifying unmet clinic needs.
Reimbursement for Services
Fee-for-service payment plans continue to play a large role in medical service reimbursement in the USA [60] . These payment plans, however, seldom account for services completed by clinical staff who are not recognized licensed providers (e.g., pharmacists) [60, 61] . The Centers for Medicare and Medicaid Services (CMS) has established chronic care management (CCM) codes that allow pharmacists and other nonprovider healthcare professionals to be reimbursed for chronic disease state management, often by means of telephone calls. In our experience, many primary care clinics are not utilizing these reimbursement codes. During discussions held with key stakeholders at primary care clinics during our intervention refinement, we found many key stakeholders: were unaware these codes existed, were not familiar enough to advocate utilization of the codes, thought these reimbursements would deduct from the clinic's current reimbursement payments, or thought they would trigger a CMS audit because the facility is using a new unfamiliar billing code. We have since provided educational sessions with interested stakeholders to overcome these misconceptions.
Stakeholder Engagement
Initiating and maintaining constructive relationships with key stakeholders may increase the likelihood an intervention is sustained. One author (BLC) is the director of the National Interdisciplinary Primary Care Network (NIPC) practicebased research network. The NIPC is composed of family care clinics, all of which have participated in at least one of our research endeavors. We have built strong relationships with clinic stakeholders by engaging them throughout intervention design, implementation, and evaluation [62] . We encourage active participation in co-authorship of results as well as keep open lines of communication to brainstorm ideas for future projects. We have identified and work with all adopter categories as defined by Rogers Diffusion of Innovations [63] and tailor our communication based on stakeholder needs.
Electronic Medical Record Access
Many studies evaluated the effect of pharmacists who are embedded within medical offices and who have complete access to the patient's medical records. Often recommendations focus on optimizing medications and dosages which require access to updated patient laboratory work, history of vitals, and other specific information that is difficult to obtain through patient interviews. However, pharmacists from community pharmacies or those providing medication therapy management by telephone usually do not have access to medical records. We have developed remote pharmacy interventions, and EMR access is necessary for our clinical pharmacists to make timely recommendations to providers and patients. These types of "virtual" clinical pharmacy services will be increasingly important for rural areas and for supplementing on-site patient visits. Lack of readiness [64] for clinics to develop service contracts and subsequent EMR access has decreased the adoption of our team-based care intervention.
Identifying Unmet Clinic Needs
Conducting a needs assessment is a systematic method for understanding unmet clinic needs [65, 66] . It also can identify current clinic procedures and help eliminate potential duplication of efforts between the current workflow and the introduced intervention. Understanding the unmet clinic needs will help align expectations between the implementers and other key stakeholders. A sustainment plan should include revisiting unmet clinic needs routinely since clinic needs may change over time and lead to disagreements and project failures.
Sustainability Frameworks
Several frameworks integrate sustainability into their core constructs and may offer clinicians and researchers insight into factors influencing intervention sustainment. Table 1 RE-AIM core elements [67] [68] [69] Reach the target population Effectiveness or efficacy of intervention Adoption of intervention by staff, settings, institutions Implementation consistency, costs, and adaptations of intervention Maintenance of intervention effects over time
The RE-AIM framework [67] [68] [69] emphasizes external validity and is a valuable tool to help improve the likelihood of sustainable adoption of evidence-based interventions. The framework consists of five "steps" to help researchers and clinicians translate research into practice (Table 1) . Forman et al. (2017) used the RE-AIM framework in conjunction with qualitative assessments to evaluate a pharmacist-led BP management intervention in three Veterans Affairs facilities [70] . Using these methods, the research team found that patients who sustained BP control also understood an association between medication adherence and BP control. The research team also uncovered factors that may influence intervention sustainment from the level of the pharmacist. For example, pharmacists were empowered to independently adjust medications and did not have to make the patient wait until after the encounter for any medication changes. The intervention did not sustain in the facilities, and authors concluded that using the RE-AIM framework with qualitative assessments was helpful for understanding why the intervention was not sustained and will be helpful in improving the intervention.
The National Health Service (NHS) Institute for Innovation and Improvement Program developed the Sustainability Model and related survey to help organizations implement and sustain effective healthcare interventions (Table 2) [71, 72] . The Sustainability Model consists of ten factors relating to process, staff, and organizational structure that may play a role in intervention sustainment. The survey is a selfassessment tool to help predict sustainability by providing an overall sustainability score. In addition to providing the sustainability score, the act of completing the Sustainability Model survey may lead to productive discussions about the intended healthcare intervention. The authors of the Sustainability Model advise users to utilize the Sustainability Model survey at several different points in time during intervention implementation and sustainment [71] . Schell et al. (2013) introduced a multilevel sustainability framework describing nine core domains influencing sustainability: Political Support, Funding Stability, Partnerships, Organizational Capacity, Program Evaluation, Program Adaptation, Communications, Public Health Impacts, and Strategic Planning. Their framework was derived from a literature review of 85 studies focused on public health program sustainability, and researchers used concept mapping to group and label domains [73] . A member of our research team (KAK) adapted the domains to assist with our ongoing clusterrandomized clinical trials to examine factors influencing sustainability of our remote pharmacist-led intervention in primary care settings (Fig. 1) . Questions derived from these domains are being used in focus groups and oneon-one interviews of key stakeholders including patients, caregivers, pharmacists, providers, and administrators. 
Conclusions
Given that a substantial proportion of the patients diagnosed with hypertension remain uncontrolled, new approaches are clearly needed to improve BP control. Multiple research studies presented in this review have demonstrated that teambased care utilizing pharmacists can improve BP management. Most studies consistently demonstrate that the most likely reason for improved BP is medication intensification and, perhaps, improved medication adherence. In addition, we presented multiple studies that demonstrated costeffectiveness of team-based approaches to BP management, especially programs involving pharmacists. However, the disparate methods used in cost evaluations make it difficult to compare results across studies and to reconcile different costeffectiveness estimates. Furthermore, the overwhelming positive outcomes of team-based care studies may be due to publication bias: unsuccessful trials may not be published. Future work is needed to determine the best populations to target with team-based BP programs and how to implement and subsequently sustain team-based approaches in diverse clinical settings. Implementation studies need to not only identify unmet clinical needs but also address reimbursement issues and stakeholder engagement.
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